PT - JOURNAL ARTICLE AU - Nieto, L Pedraza AU - Caballero, R Fernández AU - Sánchez-Hernández, JG AU - Rebollo, N AU - Pérez, MC Piñero AU - González, D García AU - Fernández, EM Sáez AU - López, MJ Otero TI - 4CPS-157 Vedolizumab: early experience and medium-term outcomes in inflammatory bowel disease AID - 10.1136/ejhpharm-2018-eahpconf.248 DP - 2018 Mar 01 TA - European Journal of Hospital Pharmacy PG - A115--A116 VI - 25 IP - Suppl 1 4099 - http://ejhp.bmj.com/content/25/Suppl_1/A115.2.short 4100 - http://ejhp.bmj.com/content/25/Suppl_1/A115.2.full SO - Eur J Hosp Pharm2018 Mar 01; 25 AB - Background Vedolizumab is a monoclonal antibody approved for the treatment of moderate to severe inflammatory bowel disease (IBD) for those patients who have had inadequate or loss of response or were intolerant to a tumour necrosis factor alpha inhibitor (anti-TNF-alpha).Purpose To assess prescribing patterns and effectiveness of vedolizumab in patients with IBD.Material and methods A retrospective review of patients with Crohn’s disease (CD) and ulcerative colitis (UC) treated with vedolizumab (July 2015–September 2017). Demographic, clinical and pharmacotherapeutic information was collected from patients’ medical records.Analysis of prescribing patterns included reasons for starting the therapy, previous treatment with anti-TNF-alpha, dosage regimen and use of an additional induction dose (week-10) of vedolizumab. Effectiveness was measured by clinical response obtained by reviewing the evolution of biochemical parameters (C-reactive protein (CRP) and faecal calprotectin (FC)) and colonoscopies findings. Effectiveness was assessed statistically using univariate and multivariate analysis.Results Forty patients (52.5% females) were included, with a median age of 48.4 years (range: 12–87) diagnosed with CD (n=21) or UC (n=19). Mean ±SD wt was 51.1±31.6 kg.Vedolizumab was prescribed in six patients because anti-TNF-alpha therapy was contraindicated. The other 34 patients had been previously treated with anti-TNF-alpha (infliximab and/or adalimumab) and changed to vedolizumab for the following reasons: anti-TNF-alpha failure despite serum anti-TNF-alpha trough levels in range (60%), adverse events (20%) and anti-drug antibodies (11.4%). A 12-year-old patient only received a dose lower than 300 mg. The dosage interval was reduced to 4 to 6 weeks in seven patients. An additional induction dose (week-10), only approved for CD, was administered to 10 patients, 50% affected by UC.52.5% of patients achieved good clinical response. CD was identified as a negative predictive factor (OR: 0.12; 95% CI: 0.03 to 0.53; p<0.001). Previous treatment with anti-TNF-alpha, shortened the dosage interval, and additional induction dose did not show significant relevance in clinical response.Conclusion For a high percentage of patients with IBD, treatment with vedolizumab was considered appropriate. In terms of effectiveness, approximately half of the patients benefited from treatment. It would be necessary to evaluate the continuity of treatment with vedolizumab in patients who did not responded to therapy.References and/or Acknowledgements 1. EPAR: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/002782/WC500168532.pdfNo conflict of interest